Molecular simulation study of CYP2B6 polymorphism with and without psoralen

被引:0
|
作者
Lu, Nan [1 ,2 ]
Meng, Fancui [3 ]
Xu, Weiren [3 ]
Tang, Lida [3 ]
Xu, Youjun [1 ,2 ]
机构
[1] Shenyang Pharmaceut Univ, Sch Pharmaceut Engn, Shenyang, Liaoning, Peoples R China
[2] Shenyang Pharmaceut Univ, Key Lab Struct Based Drug Design & Discovery, Shenyang, Liaoning, Peoples R China
[3] Tianjin Inst Pharmaceut Res, Tianjin Key Lab Mol Design & Drug Discovery, Tianjin, Peoples R China
关键词
CYP2B6; psoralen; molecular dynamics; molecular docking; mechanism-based inactivation; MECHANISM-BASED INACTIVATION; SINGLE NUCLEOTIDE POLYMORPHISM; CYTOCHROMES P450; FUNCTIONAL-CHARACTERIZATION; ALLELIC VARIANTS; STRUCTURAL BASIS; IN-SILICO; ACTIVATION; INHIBITION; EXPRESSION;
D O I
10.1080/08927022.2018.1513646
中图分类号
O64 [物理化学(理论化学)、化学物理学];
学科分类号
070304 ; 081704 ;
摘要
CYP2B6 is a polymorphic enzyme with a large number of variants which may lead to functional changes in enzyme activity and substrate selectivity. In this study, CYP2B6 and its three variants with and without psoralen, a mechanism-based inactivator, were investigated using molecular simulation method. The obtained docking orientation of psoralen was in agreement with previously identified site of metabolism. Stability analysis showed that the three variants displayed more flexibility than CYP2B6.1, and CYP2B6.34 was the most flexible one without psoralen binding. However, in the presence of psoralen, CYP2B6.34 became more rigidity. Tunnel analysis indicates that the bottleneck change of tunnels may be correlated to the increased or decreased activity of variants. Binding free energy analysis shows that van der Waals interaction dominates the binding of psoralen. CYP2B6.34 has the highest affinity to psoralen with lowest binding free energy. Ile114, Phe115 and heme contribute largely to the binding of psoralen with CYP2B6.6, while Phe206 and Leu363 play important roles for CYP2B6.1 and CYP2B6.4. These computational observations suggest that the increased activity of CYP2B6.4 and reduced activity of CYP2B6.6 may be due to changes in regional structures.
引用
收藏
页码:1402 / 1410
页数:9
相关论文
共 50 条
  • [31] The Influence of Sex, Ethnicity, and CYP2B6 Genotype on Bupropion Metabolism as an Index of Hepatic CYP2B6 Activity in Humans
    Ilic, Katarina
    Hawke, Roy L.
    Thirumaran, Ranjit K.
    Schuetz, Erin G.
    Hull, J. Heyward
    Kashuba, Angela D. M.
    Stewart, Paul W.
    Lindley, Celeste M.
    Chen, Mei-Ling
    [J]. DRUG METABOLISM AND DISPOSITION, 2013, 41 (03) : 575 - 581
  • [32] Variants in the CYP2B6 3UTR Alter In Vitro and In Vivo CYP2B6 Activity: Potential Role of MicroRNAs
    Burgess, Kimberly S.
    Ipe, Joseph
    Swart, Marelize
    Metzger, Ingrid F.
    Lu, Jessica
    Gufford, Brandon T.
    Thong, Nancy
    Desta, Zeruesenay
    Gaedigk, Roger
    Pearce, Robin E.
    Gaedigk, Andrea
    Liu, Yunlong
    Skaar, Todd C.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 104 (01) : 130 - 138
  • [33] CYP2B6 poor metaboliser alleles involved in efavirenz and nevirapine metabolism: CYP2B6*9 and CYP2B6*18 distribution in HIV-exposed subjects from Dschang, Western Cameroon
    Paganotti, Giacomo Maria
    Russo, Gianluca
    Sobze, Martin Sanou
    Mayaka, George Bouting
    Muthoga, Charles Waithaka
    Tawe, Leabaneng
    Martinelli, Axel
    Romano, Rita
    Vullo, Vincenzo
    [J]. INFECTION GENETICS AND EVOLUTION, 2015, 35 : 122 - 126
  • [34] Association of CYP2B6 G15631T polymorphism with acute leukemia susceptibility
    Berkoz, Mehmet
    Yalin, Serap
    [J]. LEUKEMIA RESEARCH, 2009, 33 (07) : 919 - 923
  • [35] A single nucleotide polymorphism of CYP2B6 found in Japanese enhances catalytic activity by autoactivation
    Ariyoshi, N
    Miyazaki, M
    Toide, K
    Sawamura, Y
    Kamataki, T
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 281 (05) : 1256 - 1260
  • [36] The role of human CYP2B6 polymorphism in the bioactivation of cyclophosphamide using CDNA expressed enzymes
    Afsharian, P.
    Teredius, Y.
    Hidestrand, M.
    Ingelman-Sundberg, M.
    Hassan, M.
    Lundgren, S.
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (02) : 70 - 71
  • [37] Meta-analysis of CYP2B6 polymorphism: Clinical evidence towards personalized therapy?
    Ansari, S.
    Duecker, C.
    Brockmoeller, J.
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2019, 392 : S57 - S57
  • [38] Synergistically Enhanced CYP2B6 Inducibility between a Polymorphic Mutation in CYP2B6 Promoter and Pregnane X Receptor Activation
    Li, Haishan
    Ferguson, Stephen S.
    Wang, Hongbing
    [J]. MOLECULAR PHARMACOLOGY, 2010, 78 (04) : 704 - 713
  • [39] EFFECTS OF A GENETIC POLYMORPHISM OF HUMAN CYP2B6 ON NICOTINE DEPENDENCE AND SMOKING CESSATION THERAPY
    Muderrisoglu, A.
    Babaoglu, E.
    Korkmaz, E. T.
    Ongun, M. C.
    Karabulut, E.
    Emri, S.
    Babaoglu, M. O.
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2018, 123 : 6 - 6
  • [40] Association between CYP2B6 polymorphism and acute leukemia in a Han population of Northwest China
    Yu, Li-Li
    Zhang, Wei
    Li, Juan
    Zhao, Li
    [J]. MOLECULAR GENETICS & GENOMIC MEDICINE, 2020, 8 (05):